Balyasny Asset Management LLC Trevena Inc Transaction History

Balyasny Asset Management LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$0.2 - $0.5 $5,829 - $14,573	29,147 New	29,147 $12,000
Q2 2021 Aug 16, 2021	SELL	$1.46 - $2.25 $57,319 - $88,335	-39,260 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$1.77 - $2.93 $69,490 - $115,031	39,260 New	39,260 $70,000
Q3 2018 Nov 14, 2018	SELL	$1.39 - $2.25 $60,938 - $98,642	-43,841 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$1.44 - $2.24 $11,999 - $18,665	8,333 Added 23.47%	43,841 $63,000
Q1 2018 May 15, 2018	SELL	$1.51 - $2.06 $16,066 - $21,918	-10,640 Reduced 23.06%	35,508 $58,000
Q4 2017 Feb 14, 2018	SELL	$1.4 - $2.6 $574,546 - $1.07 Million	-410,390 Reduced 89.89%	46,148 $74,000
Q3 2017 Nov 14, 2017	BUY	$2.22 - $2.79 $1.01 Million - $1.27 Million	456,538	456,538 $1.16 Million

Ticker TRVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 173,680,992
Market Cap $273M
Description
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV...

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Balyasny Asset Management LLC with notifications on news.